Department of Immunobiology, Poznan University of Medical Sciences, Poznan, Poland.
Chemotherapy Ward, Greater Poland Cancer Center, Poznan, Poland.
Breast Dis. 2021;40(1):33-41. doi: 10.3233/BD-201014.
Breast cancer is the most common cancer in women in Poland and worldwide. Due to growing morbidity and mortality, patients are looking for new therapeutic options. Clinical trials give cancer patients a chance to access innovative treatment often not available in the national healthcare system. Patient awareness of clinical trials is an essential element for the development of the clinical trials market.
The purpose of this survey was to obtain information from breast cancer patients about their knowledge of clinical trials.
One hundred people were invited to take part in the study, and were recruited into two groups: 50 patients diagnosed with breast cancer less than 40 years of age, and 50 patients with the same disease over 40 years of age. The survey was completed by female patients online.
Most of the subjects correctly understood the assumptions of the clinical trial; most often, both groups of subjects obtained information about medical experiments from the Internet. According to the respondents, the most important motivating factor to participate in the clinical trial was the proposed study drug and their current state of health. Patients would more frequently decide to participate in a clinical trial at the time of cancer progression compared to immediately after diagnosis. Commuting to the research center made recruitment of older patients more difficult (40% of older patients versus 16% of younger patients, p = 0.008).
Patients with breast cancer are aware of clinical trials and decide to participate in them based on the proposed study drug and their current state of health. Progression of the disease is a factor that increases the willingness to participate in clinical trials.
乳腺癌是波兰乃至全世界女性最常见的癌症。由于发病率和死亡率不断上升，患者正在寻找新的治疗选择。临床试验为癌症患者提供了获得创新治疗的机会，这些治疗通常在国家卫生保健系统中无法获得。患者对临床试验的认识是临床试验市场发展的重要因素。
本调查旨在从乳腺癌患者那里获取有关他们对临床试验的认识的信息。
邀请了 100 人参加研究，并将他们分为两组：50 名年龄在 40 岁以下的乳腺癌患者，50 名年龄在 40 岁以上的乳腺癌患者。该调查由女性患者在线完成。
大多数受试者正确理解了临床试验的假设；最常见的是，两组受试者都从互联网上获取有关医学实验的信息。根据受访者的说法，参与临床试验的最重要动机是所提议的研究药物及其当前健康状况。与诊断后立即相比，患者在癌症进展时更有可能决定参加临床试验。前往研究中心使招募老年患者变得更加困难（40%的老年患者与 16%的年轻患者相比，p=0.008）。
乳腺癌患者了解临床试验，并根据所提议的研究药物及其当前健康状况决定是否参加。疾病的进展是增加参与临床试验意愿的一个因素。
